A recent Canadian study finds that prescribing omega-3s can reduce inflammation and improve symptoms of COVID-19.
The Health Canada approved study was conducted by the Canadian Medical and Surgical Knowledge Translation Research Group.
About 100 COVID-19 positive patients have been randomized to receive Vascepa, an omega-3 fatty acid available by prescription.
At the end of the 14-day treatment period, the prevalence of symptoms decreased by 52%, according to the results of the study which noted that the treatment was well tolerated with no major side effects.
“This study provides the first evidence of an early anti-inflammatory effect of icosapent ethyl in symptomatic COVID-19 positive outpatients – who represent the majority of patients affected by this disease in the community,” said Deepak L. Bhatt, Brigham and Women’s Hospital and Harvard Medical School.
“Significant and significant improvement in patient-reported symptoms may be a safe, well-tolerated and relatively inexpensive option for influencing morbidity associated with COVID-19,” added Dr Bhatt.
The study was presented by Professor Bhatt on Saturday at the National Lipid Association conference.